In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Concentric Medical's modified neurovascular retriever:

This article was originally published in Clinica

Executive Summary

The Merci L6 Retriever, a device intended to restore blood flow in the neurovasculature by removing thrombi in patients experiencing ischaemic stroke, has received 510(k) clearance in the US. The product, developed by Concentric Medical, of Mountain View, California, is indicated for use in patients who are ineligible for, or unresponsive to, treatment with intravenous tissue plasminogen activator - clot-dissolving therapy. It may also be used in the retrieval of foreign bodies misplaced during interventional radiological procedures in the neurovasculature or the peripheral or coronary vasculature. The Merci L6 Retriever is a shaped Nitinol wire which can be delivered using standard catheterisation techniques, whereby a small puncture in the groin is used to introduce the retriever into an artery leading to the brain. Upon reaching the targeted area, the Merci retriever is deployed and returns to its original shape. The device incorporates a 2.7mm cylindrical helix with attached filaments; these provide an additional mechanism for securing the clot during retrieval.

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts